Skip to main content
SpringerLink
Log in

HCT for Germ Cell Tumors

  • Chapter
  • First Online:
Blood and Marrow Transplant Handbook

  • 1122 Accesses

Abstract:

The use of high-dose chemotherapy with autologous hematopoietic cell transplantation is well established as a potentially curative approach to patients with relapsed or refractory disease after initial cisplatin-based chemotherapy. The use of tandem transplant with high-dose carboplatin and etoposide conditioning in this setting has been a standard in the United States based on the large experience from Indiana University. Ongoing randomized trials seek to confirm this approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. American Joint Committee on Cancer. Testis. AJCC Cancer staging manual. 8th ed. New York: Springer; 2017. p. 727–35.

    Google Scholar 

  2. The International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603.

    Article  Google Scholar 

  3. Bagrodia A, Lee BH, Lee W, et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016;34:4000–7.

    Article  CAS  Google Scholar 

  4. Fizazi K, Flechon A, Le Teuff G, et al. Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). J Clin Oncol. 2016;34(15 suppl):4504.

    Article  Google Scholar 

  5. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–56.

    Article  CAS  Google Scholar 

  6. The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906–11.

    Article  Google Scholar 

  7. Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32:3085–92.

    Article  CAS  Google Scholar 

  8. Adra N, Abonour R, Althouse SK, et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol. 2017;35:1096–102.

    Article  Google Scholar 

  9. Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28:1706–13.

    Article  CAS  Google Scholar 

  10. Pico JL, Rosti G, Kramar A, et al. A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol. 2005;16:1152–9.

    Article  Google Scholar 

  11. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy with relapsed or refractory germ cell tumors: long-term results of a prospective trial. J Clin Oncol. 2012;30:800–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Hematologic Malignancies, Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

    Brandon Hayes-Lattin

Authors
  1. Brandon Hayes-Lattin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brandon Hayes-Lattin .

Editor information

Editors and Affiliations

  1. Center for Hematologic Malignancies Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

    Richard T. Maziarz

  2. Center for Hematologic Malignancies Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

    Susan Schubach Slater

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hayes-Lattin, B. (2021). HCT for Germ Cell Tumors. In: Maziarz, R.T., Slater, S.S. (eds) Blood and Marrow Transplant Handbook. Springer, Cham. https://doi.org/10.1007/978-3-030-53626-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53626-8_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53625-1

  • Online ISBN: 978-3-030-53626-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation